BACTERIAL STI / CARE & TRANSMISSION
Neisseria gonorrhoeae
Gonorrhea can affect the genitals, rectum and throat. Throat and rectal infections often cause no symptoms, so a urine test alone can miss them. It is treatable; because of antibiotic resistance, the right medicine and a follow-up check matter. [16]
Transmission risk
Risk by type of contact
Bottom line. Gonorrhea can spread through genital, anal and oral contact; deep-kissing evidence is suggestive rather than a quantified per-kiss risk. The familiar vaginal percentages come from limited historical studies, not universal modern estimates.
General
Oral
Vaginal
Anal
Kissing
What changes the risk (3)
- Doxy-PEP. HIGH for trial populations, variable magnitude: CDC 2024 summarizes approximately 50% relative reduction in gonorrhea incidence, less consistent than for chlamydia/syphilis; tetracycline resistance and geography matter. Sources 8
- Treatment and resistance. LOW for numerical transmission effect: appropriate treatment stops the current infection when successful; pharyngeal infection and antimicrobial resistance complicate clearance. No universal per-act multiplier. Sources 1
- Kissing, saliva and multiple sites. MEDIUM for association: throat infection can occur in networks with deep kissing and oral sex; no isolated probability or additive multiplier can be assigned. Sources 4
Condoms and dental dams
Specific protection is biologically and clinically supported, but a precise route-specific figure is not established here. Warner 2004 reports a combined gonorrhea/chlamydia endpoint (adjusted prevalence OR 0.42, 95% CI 0.18-0.99); it cannot be advertised as a gonorrhea-specific reduction. No dam efficacy trial. Evidence: Low Sources 1, 2
Sources for this risk profile (8)
- CDC CDC, 2021. Gonococcal Infections Among Adolescents and Adults - STI Treatment Guidelines. cdc.gov
- Warner L et al. American Journal of Epidemiology, 2004. Condom effectiveness for reducing transmission of gonorrhea and chlamydia: the importance of assessing partner infection status. DOI: 10.1093/aje/kwh044. doi.org
- CDC CDC, 2024. About STI Risk and Oral Sex. cdc.gov
- Charleson F et al. Sexually Transmitted Diseases, 2023. A systematic review of kissing as a risk factor for oropharyngeal gonorrhea or chlamydia. DOI: 10.1097/OLQ.0000000000001777. research.monash.edu
- Platt R, Rice PA, McCormack WM JAMA, 1983. Risk of acquiring gonorrhea and prevalence of abnormal adnexal findings among women recently exposed to gonorrhea. pubmed.ncbi.nlm.nih.gov
- Holmes KK, Johnson DW, Trostle HJ American Journal of Epidemiology, 1970. An estimate of the risk of men acquiring gonorrhea by sexual contact with infected females. DOI: 10.1093/oxfordjournals.aje.a121125. academic.oup.com
- Hooper RR et al. American Journal of Epidemiology, 1978. Cohort study of venereal disease. I: the risk of gonorrhea transmission from infected women to men. DOI: 10.1093/oxfordjournals.aje.a112597. pubmed.ncbi.nlm.nih.gov
- Bachmann LH et al.; CDC MMWR Recommendations and Reports, 2024. CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024. DOI: 10.15585/mmwr.rr7302a1. cdc.gov
* How to read these figures. Each is a published estimate under the conditions shown beside it, usually an untreated partner and a single act or partnership. It is not a prediction of your personal risk.
- Evidence: High
- Several prospective studies or a systematic review broadly agree.
- Evidence: Medium
- One or two studies, wide uncertainty, or a model.
- Evidence: Low
- Guideline judgment, case reports, or extrapolation.
Where no risk level is shown, the evidence cannot rank it. That is not the same as low.
Evidence reviewed through 2026-10-27. For reference only; not medical advice.
When to test after a possible exposure
About 14 days is a pragmatic NAAT testing point after an asymptomatic exposure, not a guarantee that earlier infection is undetectable.
When to be seen sooner. Discharge, pain when urinating, rectal or eye symptoms, or contact with someone who has a confirmed result are reasons to be seen without waiting two weeks.
-
Gonorrhea NAAT; culture where indicated
Public services commonly use 2 weeks; BASHH explicitly describes limited evidence and a pragmatic approach to testing contacts.
Test when symptoms or a known contact are assessed; after an early negative, repeat at approximately 2 weeks if clinically indicated.
Specimens: First-pass urine / genital swab; Throat swab for relevant exposure; Rectal swab for relevant exposure
Sources 1, 2, 3
Early negatives, after treatment, and screening limits
An early negative result. A negative genital specimen does not exclude throat or rectal infection. An early negative may need repeat sampling at the relevant sites.
After treatment. CDC: pharyngeal gonorrhea needs test of cure 7-14 days after initial treatment; testing at 7 days increases false-positive NAAT risk. Routine test of cure is not required for uncomplicated genital/rectal infection treated as recommended. Retesting around 3 months addresses reinfection.
Screening limits. Culture is important for suspected treatment failure and resistance assessment; a negative result is not a universal all-site clearance statement.
Kissing and body sites. A throat swab is the relevant specimen for pharyngeal infection. Deep-kissing evidence does not establish a separate validated per-kiss testing window or a requirement for routine testing after every kiss.
Sources for testing guidance (3)
- NHS inform, Scotland. STI testing at home. Live guidance. nhsinform.scot
- BASHH. Gonorrhoea 2018: pragmatic testing of contacts. 2018. bashh.org
- CDC STI Treatment Guidelines. Gonococcal Infections Among Adolescents and Adults. 2021. cdc.gov
Treatment
Ceftriaxone remains central in CDC guidance, with chlamydia treatment added when needed. In December 2025, FDA approved oral zoliflodacin and gepotidacin for specified uncomplicated urogenital cases. Those approvals do not make either an interchangeable treatment for throat or rectal infection. Local availability and resistance guidance govern prescribing. [16][18][19]
Actions
1. Include the throat when relevant. Discuss throat NAAT after oral exposure and rectal NAAT after anal exposure, as well as genital testing. Persistent infection or suspected treatment failure may require culture and susceptibility testing. [16][61]
2. Tell recent partners. US guidance uses the 60 days before symptoms or diagnosis, plus the most recent partner even if earlier. Partners with direct sexual contact in that window can be offered testing and treatment, and the clinic advises who needs what. An early negative result does not cover a very recent exposure. [16]
3. Check the right endpoint. Wait seven days after treatment, and until partners are treated, before having sex. Throat infection is rechecked with a test of cure 7-14 days after treatment; an early positive NAAT may need culture to confirm it. A retest at three months checks for reinfection. [16]
SCIENCE & CONTEXT
Gonorrhea / the evidence
History
The gonococcus was identified in 1879. Over the following century, successive antibiotics transformed treatment, but the organism repeatedly developed resistance. The 2025 US approvals of two oral agents are meaningful progress, yet their site-specific indications illustrate why a new drug is not a universal solution. [18][19][20]
Impact
N. gonorrhoeae infects mucous membranes. It can cause painful urination, discharge, pelvic pain or rectal inflammation, and throat infection very often causes no symptoms. Untreated genital infection can lead to pelvic inflammatory disease or epididymitis and affect fertility; rarely, it spreads through the blood to the joints or elsewhere. Treatment prevents these complications. [16]
The throat matters because infection there can be harder to clear and can go unnoticed. A test of cure checks that treatment worked; a three-month retest checks for a new infection. They answer different questions, and neither is the same as a panel being "all clear". [16]
Probability at a glance
| Measure | Estimate | Interpretation |
|---|---|---|
Condomless act | 20-50% | Conditional on infected source; broad guidance estimate |
Correct barrier use | High protection | No universal residual percentage |
One Swedish club sample | 0 detected / 235 | Genital sample only; not proof of zero prevalence |
These are different denominators. The per-act figure is conditional on an infected source partner; the club observation is a small sample result, not proof that a community has zero infection. [04][17]
A general sex-party prevalence has not been established well enough to justify a single six-month partner-risk table here. Use local, anatomically matched prevalence before applying the appendix formula.